Comparative Pharmacology
Head-to-head clinical analysis: CARMOL HC versus DERMATOP E EMOLLIENT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARMOL HC versus DERMATOP E EMOLLIENT.
CARMOL HC vs DERMATOP E EMOLLIENT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carmol HC is a combination of urea (a keratolytic) and hydrocortisone (a corticosteroid). Urea softens and dissolves the intercellular matrix of the stratum corneum, promoting desquamation and enhancing penetration of hydrocortisone. Hydrocortisone suppresses inflammation by induction of phospholipase A2 inhibitory proteins, collectively called lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.
Prednicarbate is a corticosteroid that binds to the glucocorticoid receptor, leading to inhibition of phospholipase A2, decreased release of arachidonic acid, and reduced synthesis of prostaglandins, leukotrienes, and other inflammatory mediators.
Apply a thin film to affected area twice daily; topical, not for ophthalmic or oral use.
Apply a thin layer topically to affected areas twice daily. Maximum 3-week course.
None Documented
None Documented
1-2 hours (hydrocortisone acetate); clinical effects persist longer due to local anti-inflammatory action; tissue half-life not well defined.
Terminal elimination half-life: 18-36 hours. Clinically, once-daily dosing maintains therapeutic effect.
Primarily renal excretion of metabolites (40-60%) as glucuronide and sulfate conjugates; <10% unchanged; biliary/fecal elimination accounts for <20%.
Predominantly hepatic metabolism; renal excretion of metabolites <5% unchanged; biliary/fecal excretion minimal.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid